Gastrointestinal Cancer News

CHICAGO — Researchers at Digestive Disease Week reported undergoing colonoscopy resulted in significant reductions in colorectal cancer mortality rates among veterans, particularly in left-sided cancer, according to data presented.

CHICAGO — Researchers linked an increased fiber intake among patients with colorectal cancer with a lower risk of cancer-related mortality, according a study presented at Digestive Disease Week.

Applied Proteomics, a company that develops proteome-based blood tests for early detection and monitoring of diseases, has partnered with health care cost management solutions provider MultiPlan, thus expanding access to the company’s colorectal cancer blood test to 50 to 75 million people in the MultiPlan network.

Most patients with rectal cancer who follow a watch-and-wait approach successfully avoided radical surgery, according to results of a study review.

Patients with pancreatic cancer who smoked near the time of diagnosis were 40% more likely to die after diagnosis than those who never smoked or stopped smoking before diagnosis, according to a prospective study published in Journal of Clinical Oncology.

Among patients with gastric intestinal metaplasia, the risk for dysplasia or early gastric cancer was increased in men and in patients with incomplete gastric intestinal metaplasia, according to the results of a 5-year retrospective cohort study.

Nivolumab appeared safe and effective in patients with advanced liver cancer who did not respond to sorafenib, according to results from the CheckMate 040 study presented at the International Liver Congress 2017.

During his presidency, former U.S. President Barack Obama officially proclaimed April as National Cancer Control Month to “move forward in the fight against cancer” by improving the prevention, detection and treatment of cancer.

Follow-up surveillance colonoscopy after resection of intermediate-risk adenomas was associated with a reduced incidence of colorectal cancer in the U.K., according to research published in the Lancet Oncology.

The FDA expanded the approval of regorafenib to include the treatment of patients with hepatocellular carcinoma who have been previously treated with sorafenib.